A dose-reduction HPV vaccine immunobridging trial of two HPV vaccines among adolescent girls in Tanzania (the DoRIS trial) – Study protocol for a randomised controlled trial

BACKGROUND: Human papillomavirus (HPV) infection is the primary cause of cervical cancer. In 2018, the World Health Organization (WHO) Director General announced his commitment to eliminate cervical cancer, with HPV vaccination as a priority. However, the costs of setting up a multi-dose HPV vaccina...

Descripción completa

Detalles Bibliográficos
Autores principales: Baisley, Kathy J., Whitworth, Hilary S., Changalucha, John, Pinto, Ligia, Dillner, Joakim, Kapiga, Saidi, de Sanjosé, Silvia, Mayaud, Philippe, Hayes, Richard J., Lacey, Charles J., Watson-Jones, Deborah
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7970022/
https://www.ncbi.nlm.nih.gov/pubmed/33421649
http://dx.doi.org/10.1016/j.cct.2021.106266

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7970022/
https://www.ncbi.nlm.nih.gov/pubmed/33421649
http://dx.doi.org/10.1016/j.cct.2021.106266

Ejemplares similares